Brimonidine
Active ingredient: Brimonidine Tartrate
In short: Brimonidine topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older.
What is Brimonidine used for?
Brimonidine topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older.
Brimonidine dosage
Apply a pea-sized amount once daily to each of the five areas of the face: central forehead, chin, nose, each cheek. Brimonidine topical gel should be applied smoothly and evenly as a thin layer across the entire face avoiding the eyes and lips.
Wash hands after applying brimonidine topical gel.
Brimonidine topical gel is for topical use only and not for oral, ophthalmic, or intravaginal use.
How to take Brimonidine — instructions & advice from the label
See FDA-approved patient labeling (Patient Information and Instructions for Use). Patients using brimonidine topical gel should receive the following information and instructions:
•This medication is to be used as directed by the physician.
•It is for external use only.
•Brimonidine topical gel should not be applied to irritated skin or open wounds.
•Avoid contact with the eyes and lips.
•Patients should wash their hands immediately after applying the medication.
•Some patients using brimonidine topical gel may experience erythema, flushing or excessive whitening.
•Patients should report any adverse reactions to their physician.
•Keep out of reach of children.
Manufactured by Padagis®
Yeruham, Israel
www.padagis.com
Rev 07-24
7M15B RC PH3
Warnings & precautions
Do not take this medicine if: Brimonidine topical gel is contraindicated in patients who have experienced a hypersensitivity reaction to any component. Reactions have included angioedema, urticarial, and contact dermatitis .
Brimonidine topical gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thrombangiitis obliterans, scleroderma, or Sjögren’s syndrome.
Alpha-2 adrenergic agonists can lower blood pressure. Brimonidine topical gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease.
Two young children of a subject in a clinical trial experienced serious adverse reactions following accidental ingestion of brimonidine topical gel. Adverse reactions experienced by one or both children included lethargy, respiratory distress with apneic episodes (requiring intubation), sinus bradycardia, confusion, psychomotor hyperactivity, and diaphoresis. Both children were hospitalized overnight and discharged the following day without sequelae.
Keep brimonidine topical gel out of the reach of children.
Postmarketing cases of bradycardia, hypotension (including orthostatic hypotension) and dizziness have been reported. Some cases required hospitalization. Some cases involved application of brimonidine topical gel in unapproved dosing regimens and for unapproved indications, including the application of brimonidine topical gel following laser procedures.
Avoid applying brimonidine topical gel to irritated skin or open wounds.
Erythema
Some subjects in the clinical trials discontinued use of brimonidine topical gel because of erythema. Some subjects in the clinical trials reported a rebound phenomenon, where erythema was reported to return worse compared to the severity at baseline. …
Brimonidine side effects
The following adverse drug reactions are discussed in greater detail in other sections of the label:
•Systemic Adverse Reactions of Alpha-2 Adrenergic Agonists
•Local Vasomotor Adverse Reactions
•Hypersensitivity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
During clinical trials, 1210 subjects were exposed to brimonidine topical gel. A total of 833 subjects were treated for persistent (nontransient) erythema associated with rosacea, and 330 of those were treated once daily for 29 days in vehicle-controlled trials.
Adverse reactions that occurred in at least 1% of subjects treated with brimonidine topical gel once daily for 29 days and for which the rate for brimonidine topical gel exceeded the rate for vehicle are presented in Table 1. …
Drug interactions
Alpha-2 agonists, as a class, may reduce blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised.
Although specific drug-drug interactions studies have not been conducted with brimonidine topical gel, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anaesthetics) should be considered.
Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.
About this medicine
Brimonidine Topical Gel, 0.33% contains brimonidine tartrate, an alpha adrenergic agonist.
The molecular formula of brimonidine tartrate is C11H10BrN5 • C4H6O6. It has the following structural formula:
Chemically, brimonidine tartrate is 5-Bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate. Brimonidine tartrate has a molecular weight of 442.24 and appears as white to slightly yellowish powder.
Each gram of Brimonidine Topical Gel, 0.33% contains 5 mg of the active ingredient brimonidine tartrate (equivalent to 3.3 mg of brimonidine free base), in a white to light yellow opaque gel composed of the inactive ingredients benzalkonium chloride, carbomer homopolymer type B, glycerin, propylene glycol, purified water, sodium hydroxide, and talc.
How it works: Brimonidine is a relatively selective alpha-2 adrenergic agonist. Topical application of brimonidine topical gel may reduce erythema through direct vasoconstriction. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c899b329-cc5e-4443-8e94-451314de47c9. Read the full official label on DailyMed.
Related medicines
Doxycycline Adalimumab Ketoconazole Levocetirizine Cyclosporine Tretinoin Dupilumab Isotretinoin